Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients who have completed core study CLAF237A1303.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Diagnosis as Type 2 Diabetes

• Patients who have completed study CLAF237A1303

• Outpatients

Exclusion Criteria:

• Patients who prematurely discontinued Study CLAF237A1303

• Other protocol-defined inclusion/exclusioncriterial may apply